Teva Launches AHZANTIVE, Aflibercept Biosimilar, to Capture €1.5 bn EU Market Share
Teva launches AHZANTIVE, a cost‑effective aflibercept biosimilar, targeting 15% EU market share and $1.5 bn sales—showing how strategic partnerships accelerate biosimilar growth.
4 minutes to read